



| 2025  
(Pharmacy)

# GNIPST BULLETIN

Volume-3, Issue- 3



**GURU NANAK INSTITUTE OF PHARMACEUTICAL  
SCIENCE AND TECHNOLOGY**

157/F, Nilgunj Road, Kolkata- 700114, West Bengal, India



# Table of Contents

01 Message from Director and Principal

02 Recent Researches

03 New Drug Approvals

04 Clinical Trial News

05 Disease Outbreak News

06 Campus News

07 Special Page and Game time







## MESSAGE FROM HONORABLE DIRECTOR

As the Director of Guru Nanak Institute of Pharmaceutical Science and Technology, I extend my heartfelt greetings to our academic community and well-wishers on the joyous occasion of Teachers' Day.

This day is a profound reminder of the invaluable role that teachers play in shaping minds, nurturing curiosity, and guiding generations towards knowledge, character, and excellence. It is an occasion to honour their dedication, perseverance, and selfless commitment to empowering students and building a brighter future for our nation.

At GNIPST, we take immense pride in our faculty who embody these ideals through their passion for teaching, innovation in learning, and unwavering support for our students' holistic growth. Their efforts continue to inspire a culture of academic excellence, ethical leadership, and social responsibility within our institution.

Let us celebrate this day by reaffirming our collective commitment to the noble mission of education—fostering inquisitive minds, igniting young potential, and guiding them to become compassionate and capable leaders in Pharmaceutical Sciences.

Wishing all our teachers and mentors continued success, fulfillment, and happiness on this special day.

**Happy Teachers' Day!**

*Prof. (Dr.) Abhijit Sengupta*

## MESSAGE FROM HONORABLE PRINCIPAL

I extend my warm greetings and best wishes to our students, faculty, staff, alumni, and valued partners on the joyous occasion of Teachers' Day. May this day inspire us all with renewed commitment, compassion, and dedication to the noble mission of education.

At Guru Nanak Institute of Pharmaceutical Science and Technology (GNIPST), we deeply value the pivotal role of our teachers in shaping the minds and character of future leaders in pharmaceutical sciences. Since our inception in 2005, GNIPST has grown into a distinguished centre of pharmacy education—recognized by the Pharmacy Council of India (PCI) and honoured as the first pharmacy institution in the region to achieve both NAAC and NBA accreditations. Our recent achievement of securing the 85th rank in NIRF 2025 stands as a testament to the relentless efforts of our faculty, whose guidance, mentorship, and scholarly excellence continue to drive our institution forward.

Teachers are the true architects of knowledge, igniting curiosity and nurturing values that last a lifetime. As we celebrate this special day, let us reaffirm our mission to foster innovation, inspire young minds, and empower our students to become not only competent professionals but also compassionate, responsible global citizens.

Let us move forward together with integrity, passion, and a shared vision—upholding the transformative power of education to build a brighter and more enlightened future.

Wishing all our teachers and mentors happiness, fulfillment, and continued success on this Teachers' Day.

**Happy Teachers' Day!**

*Prof. (Dr.) Lopamudra Datta*





## RECENT RESEARCHES



**WHO designates new WHO-Listed Authorities, strengthening global access to quality-assured medical products**

**MORE INFO**

[www.who.int/](http://www.who.int/)

The World Health Organization (WHO) has officially designated Health Canada, the Ministry of Health, Labour and Welfare/Pharmaceuticals and Medical Devices Agency (MHLW/PMDA) of Japan, and the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom as WHO-Listed Authorities (WLAs), a status granted to national authorities that meet the highest international regulatory standards for medical products. With these latest designations, WHO expands the growing list of WLAs, now involving 39 agencies across the world, supporting faster and broader access to quality-assured medical products, particularly in low- and middle-income countries (LMICs). In addition, the Republic of Korea's Ministry of Food and Drug Safety (MFDS) – one of the first regulatory authorities to complete the WLA assessment for both medicines and vaccines in October 2023 – has had its listing scope successfully expanded, now covering all regulatory functions.

**Kenya achieves elimination of human African trypanosomiasis or sleeping sickness as a public health problem**

**MORE INFO**

[www.who.int/](http://www.who.int/)

The World Health Organization (WHO) has validated Kenya as having eliminated human African trypanosomiasis (HAT) or sleeping sickness as a public health problem, making it the tenth country to reach this important milestone. HAT is the second neglected tropical disease (NTD) to be eliminated in Kenya: the country was certified free of Guinea worm disease in 2018.

**Circulating vaccine-derived poliovirus type 1- Israel**

**MORE INFO**

[www.who.int/](http://www.who.int/)

On 4 August 2025, Israel notified WHO of a circulating vaccine-derived poliovirus type 1 (cVDPV1) outbreak. Between February and July 2025, nine genetically linked virus isolates were found in environmental samples from seven sites, mainly in Jerusalem and the Central Region. No human cases of paralytic polio have been reported. Israel discontinued routine use of the bivalent oral polio vaccine in March 2025 but continues using inactivated polio vaccine (IPV) as part of the country's routine immunization schedule. WHO and partners of the Global Polio Eradication Initiative are supporting national and subnational authorities. WHO assesses the risk of international spread of this cVDPV1 outbreak in Israel as low, due to strong overall immunity, surveillance, and response systems. However, the virus is circulating in under-vaccinated, vaccine-sceptic communities with ties to similar groups abroad, posing a potential risk for further spread.





FDA



# NEW DRUG APPROVALS

August, 2025

## Modeyso (dordaviprone) Capsules

- Company: Jazz Pharmaceuticals plc
- Date of Approval: August 6, 2025
- Treatment for: Malignant Glioma



## KETARx (ketamine hydrochloride) Injection

- Company: PharmaTher Holdings Ltd.
- Date of Approval: August 7, 2025
- Treatment for: Pain



## Hernexeos (zongertinib) Tablets

- Company: Boehringer Ingelheim Pharmaceuticals, Inc.
- Date of Approval: August 8, 2025
- Treatment for: Non Small Cell Lung Cancer



## Brinsupri (brensocatib) Tablets

- Company: Insmed Incorporated
- Date of Approval: August 12, 2025
- Treatment for: Bronchiectasis



## Papzimeos (zopapogene imadenovec-drba) Injection

- Company: Precigen, Inc.
- Date of Approval: August 14, 2025
- Treatment for: Recurrent Respiratory Papillomatosis



## Dawnzera (donidalorsen) Injection

- Company: Ionis Pharmaceuticals, Inc.
- Date of Approval: August 21, 2025
- Treatment for: Hereditary Angioedema



## Wayrilz (rilzabrutinib) Tablets

- Company: Sanofi
- Date of Approval: August 29, 2025
- Treatment for: Immune Thrombocytopenia



<https://www.drugs.com/newdrugs.html>



# CLINICAL TRIAL NEWS



01.

## Allogene Therapeutics Moves Forward with Standard Fludarabine and Cyclophosphamide (FC) Lymphodepletion Regimen in the ALPHA3 Trial for Cemacabtagene Ansedleleucel (Cema-Cel) in First-Line Consolidation for Large B-Cell Lymphoma

SOUTH SAN FRANCISCO, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it has selected standard fludarabine and cyclophosphamide (FC) as the lymphodepletion regimen to be used in its ALPHA3 study evaluating cemacabtagene ansedleleucel (cema-cel) in first-line consolidation for large B-cell lymphoma (LBCL).

02.

## U.S. FDA Granted Fast Track Designation to Dizal's Birelentinib for Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

August 6, 2025 – Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its Birelentinib (DZD8586) for the treatment of adult patients with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.

03.

## Boehringer and Click Therapeutics' Investigational Prescription Digital Therapeutic CT-155 Meets Primary Endpoint in CONVOKE Study for Negative Symptoms in Schizophrenia

Ingelheim, Germany / Ridgefield, Connecticut / New York, New York, Thu, August 7, 2025 -- Boehringer Ingelheim and Click Therapeutics today announced that the pivotal Phase III CONVOKE study (NCT05838625) of CT-155 (BI 3972080), an investigational prescription digital therapeutic (PDT), met its primary endpoint. The randomized, double-blind, controlled study investigated the effectiveness and safety of CT-155 versus a digital control app as an adjunct to standard of care antipsychotic therapy in people diagnosed and living with schizophrenia experiencing negative symptoms.

04.

## Novartis Ianalumab Phase III Trial Meets Primary Endpoint in ITP, Demonstrating Statistically Significant Improvement in Time to Treatment Failure

Basel, August 12, 2025 – Novartis today announced positive top-line results from VAYHIT2, a Phase III trial evaluating ianalumab plus eltrombopag in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids<sup>1,2</sup>. Ianalumab plus eltrombopag, compared to placebo plus eltrombopag, significantly prolonged the time to treatment failure (TTF), the primary endpoint that assesses how long patients maintain safe platelet levels during and after the treatment period. Ianalumab is being investigated in other B cell-driven autoimmune diseases, including ongoing Phase III trials in first-line ITP and in second and later lines of warm autoimmune hemolytic anemia, with readouts expected in 2026.

05.

## Halda Therapeutics Receives FDA Fast Track Designation for HLD-0915 for the Treatment of Metastatic Castration-Resistant Prostate Cancer

NEW HAVEN, CT, August 14, 2025 — Halda Therapeutics, a clinical-stage biotechnology company developing a novel class of therapies called RIPTAC™ Therapeutics, today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to HLD-0915, the company's lead development candidate, for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

06.

## Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Redmond, WA and Princeton, NJ – August 18, 2025 – SystImmune Inc. (SystImmune), a clinical-stage biotechnology company, and Bristol Myers Squibb today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to izalontamab brengitecan (iza-bren) for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy.

07.


## Baxdrostat Demonstrated Statistically Significant and Clinically Meaningful Reduction in Systolic Blood Pressure in Patients with Hard-to-Control Hypertension in the BaxHTN Phase III Trial

30 August 2025 -- Positive full results from the BaxHTN Phase III trial showed baxdrostat demonstrated a statistically significant and clinically meaningful reduction in mean seated systolic blood pressure (SBP) at two doses (2mg and 1mg) compared with placebo at 12 weeks. Results were seen in patients with hard-to-control (uncontrolled and resistant) hypertension who received baxdrostat or placebo on top of standard of care. These data were presented today in a Hot Line session at the European Society of Cardiology (ESC) Congress 2025 and also simultaneously published in the New England Journal of Medicine.

MORE INFORMATION >>

[https://www.drugs.com/clinical\\_trials\\_archive/january-2025.html](https://www.drugs.com/clinical_trials_archive/january-2025.html)





August, 2025

**29th August, 2025**

The global cholera situation continues to deteriorate, driven by conflict and poverty, posing a significant public health challenge across multiple WHO regions. Between 1 January and 17 August 2025, a total of 409 222 cholera/Acute Watery Diarrhoea (AWD) cases and 4738 deaths were reported globally, from 31 countries, with six of the 31 countries reporting case fatality rates above 1%, indicating serious gaps in case management and delayed access to care. Cholera is resurging in a number of countries, including some that had not reported substantial case numbers in years, like Chad and the Republic of Congo, while other countries, such as the Democratic Republic of the Congo, South Sudan, and Sudan, are experiencing outbreaks that are continuing from 2024, with significant geographic expansion. This complicates containment efforts and strains fragile health systems. Conflict, mass displacement, disasters from natural hazards, and climate change have intensified outbreaks, particularly in rural and flood-affected areas, where poor infrastructure and limited healthcare access delay treatment. These cross-border factors have made cholera outbreaks increasingly complex and harder to control. Safe drinking water, sanitation and hygiene are the only long-term and sustainable solutions to ending this cholera emergency and preventing future ones. Given the scale, severity, and interconnected nature of these outbreaks, the risk of further spread within and between countries is considered very high. Without urgent and coordinated public health measures, based on strengthened surveillance, improved case management, This initiative follows the commitment of African Heads of State and Government, who have elevated cholera to a continental priority through their recent high-level Call to Action, pledging to control and eliminate outbreaks by 2030.



**MORE  
INFO**



<https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON573>

## ***Ebola virus disease - Democratic Republic of the Congo***

5th September, 2025

## Situation at a glance

On 1 September 2025, WHO received an alert from the Ministry of Health of the Democratic Republic of the Congo (DRC) regarding suspected cases of Ebola virus disease (EVD) in the Bulape Health Zone, Kasai Province, DRC. The first known index case was a pregnant woman who presented at Bulape General Reference Hospital on 20 August 2025 with symptoms of high fever, bloody diarrhoea, haemorrhage and extreme weakness. She died on 25 August from multiple organ failure. On 4 September 2025, following confirmatory laboratory testing, the Ministry of Health declared an outbreak of EVD. Ebola virus disease is a serious, often fatal illness in humans. The virus is transmitted to humans through close contact with the blood or secretions of infected wildlife and then spreads through human-to-human transmission. As of 4 September 2025, 28 suspected cases, including 15 deaths (case fatality ratio (CFR): 54%), have been reported from three areas of the Bulape health zone (Bulape, Bulape Com and Dikolo) and Mwaka health zone. Among the deaths, four are health-care workers.




**MORE  
INFO**

<https://www.who.int/emergencies/disease-outbreak-news/item/2025-DON566>


# Happy Teacher's Day

On the occasion of Teacher's Day, GNIPST took the initiative to provide our students with a unique opportunity to conduct classes for their juniors, symbolizing respect and gratitude towards their teachers. A total of **20 UG final year** students and **25 PG final year** students conducted the sessions. They shared that the experience was very enriching, while the juniors also expressed how much they enjoyed and learned from the classes. The celebrations were further enriched with vibrant programs, where students conveyed their heartfelt love and appreciation for their mentors. Some glimpses of the event are attached below.






# GNIPST GAME TIME



## Cross Word (Ph- 8).



### Across

3. you use to hear the gut sounds
4. what you use to take a temperature
6. helps you see better in the dark
7. great for creating a hoof boot
9. make you have plenty on hand
10. helps flush wounds
11. a type of non stick bandage

### Down

1. used to cut of a bandage
2. great for keeping bandages clean
5. a stretchable top bandage
8. used to dry the wound area before bandaging

*Stay tuned for to the next edition for a shout out to fastest correct answers!*

**Submit your answer**



SCAN  
ME

or

CLICK  
HERE

## Celebrating the Achievers!


Volume -3, Issue -1



**Neha Mondal**  
B.Pharm, 5th Semester



# CAMPUS NEWS



**1. Placement:** GNIPST is very proud to share that **Aikya Dutta**, B. Pharm Class of 2025, GNIPST, for securing placement with Nestle India Limited. His dedication, perseverance, and hard work have brought this proud achievement. We wish her continued success and many more milestones in her professional journey ahead.



**2. Placement:** GNIPST is very proud to share that **Arijit Manna**, M. Pharm Class of 2025, GNIPST, for securing placement at Torrent Pharma. His hard work and dedication have truly paid off. We wish him continued success and growth in this new phase of his professional journey.



**3. Career Orientation Program:** GNIPST organized a Career Orientation Program on “KAR LO SAFALTA MUTTHI MAIN I.P.L” in collaboration with the P&G Health & Hygiene Team on 2nd September 2025 at 2:00 PM. The session provided students with valuable career insights and professional guidance.



**4. Health Awareness Seminar:** GNIPST organized an Oral Health Awareness Seminar on 5th September 2025 in collaboration with Guru Nanak Institute of Dental Science and Research. The session emphasized the importance of oral hygiene and healthy practices, offering valuable insights from experts.



**5. Induction Program:** GNIPST warmly welcomed the B.Pharm 1st Year students with the commencement of the Student Induction Program. The program marked the beginning of an exciting journey of learning, growth, and innovation. Students were introduced to the academic culture, values, and future opportunities awaiting them. The institute extended best wishes for a successful and inspiring academic journey ahead.





## Editor-in-Chief

*Prof. (Dr.) Abhijit Sengupta*

## Managing Editors

Prof. (Dr.) Lopamura Datta

## Associate Editors

Mr. Tushar Adhikari

Ms. Manjarima Ganguli

## Editorial Board Members

Mrs. Indrani Banerjee Chakraborty

Mr. Arpan Dutta

Ms. Ananya Chandra

Ms. Parnasree Chakraborty

Ms. Lopamudra Saha

Mr. Sarthak Saha



## COURSES OFFERED

### PHARMACY UG COURSES

- Bachelor of Pharmacy (B.Pharm)

### PHARMACY DIPLOMA COURSES

- Diploma in Pharmacy (D.Pharm)

### PHARMACY PG COURSES

- M.Pharm in Pharmaceutics
- M.Pharm in Pharmacology
- M.Pharm in Pharmaceutical Chemistry
- M.Pharm in Quality assurance
- M.Pharm in Regulatory Affairs
- M.Pharm in Pharmacognosy
- M.Pharm in Pharmaceutical Biotechnology

Major  
Recruiters

**Cipla**  
**ZIF**  
RnD SOLUTIONS

**Cognizant**  
 **Nestlé**

  
**wipro**  
 **TRIMLIN**

  
**IQVIA**  
 **FRESENIUS  
KABI**

**MACLEODS**  
 **tcs**

**Latest  
news**



[www.gnipst.ac.in](http://www.gnipst.ac.in)



[www.facebook.com](http://www.facebook.com)



[www.instagram.com](http://www.instagram.com)



[www.linkedin.com](http://www.linkedin.com)



[www.youtube.com](http://www.youtube.com)



[api.whatsapp.com](http://api.whatsapp.com)